FDA Brief

Warning letters Devices

FDA warning letter to

Abbott Diabetes Care, Inc.

High riskIssued Jan 23Posted Feb 3Center for Devices and Radiological Health

FDA warns Abbott Diabetes Care that FreeStyle Libre 3 glucose monitors lacked design transfer and finished-device accuracy release testing.

What happened

During an inspection at Abbott's Alameda, CA facility from October 14 to October 23, 2025, FDA found that Abbott did not transfer glucose accuracy specifications to third-party manufacturers and did not test finished, sterilized, packaged FreeStyle Libre devices for accuracy before release. FDA reviewed Abbott's responses dated November 14 and December 19, 2025, and found them inadequate.

What FDA found

  1. Abbott did not have adequate procedures to move design performance requirements into production specifications for third-party manufacturers.

    21 CFR 820.30(h)
  2. Abbott released finished FreeStyle Libre devices without testing fully assembled, sterilized, programmed, and packaged devices for glucose accuracy before distribution.

    21 CFR 820.80(d)
  3. Abbott did not establish statistically valid acceptance criteria and sampling plans for finished-device release.

    21 CFR 820.250(a)
  4. Abbott did not adequately prove that its manufacturing and release control preserves the device's accuracy performance.

    21 CFR 820.30(g); 21 CFR 862.1355(b)(3)

What FDA wants

FDA asks Abbott to respond in writing within 15 business days with specific corrections and corrective actions to address the violations and prevent recurrence, including a timetable if work will take longer.

Who should pay attention

  • patients who use FreeStyle Libre glucose monitors
  • healthcare providers who rely on continuous glucose monitoring readings
  • contract manufacturers and distributors of finished glucose monitoring devices

This is a summary. Read the original letter on fda.gov.

Abbott Diabetes Care, Inc.'s FDA history

Recalls in the last 12 months

Jan 21 Class I Abbott Diabetes Care, Inc.
Device
FreeStyle Libre 3 Sensor REF 72081-01 UDI-DI code: 00357599818005 The FreeStyle Libre 3 sensor is a component of the FreeStyle Libre 3 Continuous Glucose Monitoring System.
Due to a manufacturing process issue that may cause carbon build up in the sensor that may result in incorrect low glucose results
Jan 21 Class I Abbott Diabetes Care, Inc.
Device
FreeStyle Libre 3 Plus Sensor REF 78768-01 UDI-DI code: 00357599844011 The FreeStyle Libre 3 Plus sensor is a component of the FreeStyle Libre 3 Continuous Glucose Monitoring System.
Due to a manufacturing process issue that may cause carbon build up in the sensor that may result in incorrect low glucose results
Jan 21 Class I Abbott Diabetes Care, Inc.
Device
FreeStyle Libre 3 Plus Sensor REF 78769-01 UDI-DI code: 00357599843014 The FreeStyle Libre 3 Plus sensor is a component of the FreeStyle Libre 3 Continuous Glucose Monitoring System.
Due to a manufacturing process issue that may cause carbon build up in the sensor that may result in incorrect low glucose results
Jan 21 Class I Abbott Diabetes Care, Inc.
Device
FreeStyle Libre 3 Plus Sensor REF 72080-01 UDI-DI code: 00357599819002 The FreeStyle Libre 3 Plus sensor is a component of the FreeStyle Libre 3 Continuous Glucose Monitoring System.
Due to a manufacturing process issue that may cause carbon build up in the sensor that may result in incorrect low glucose results

Full company page

Similar letters to other companies

  1. Hologic, Inc.

    FDA warns Hologic over design-control and reporting failures for implantable BioZorb markers, including missed medical device reports and a correction report.

    High risk
  2. MicroVention Costa Rica S.R.L.

    FDA says MicroVention Costa Rica's catheters and balloons are adulterated due to quality-system and process-validation failures.

    Medium